---
title: "ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290690105.md"
description: "The company is anticipating a planned reduction of around 17% in its workforce, with estimated annual savings of about $10 million. This move is aimed at increasing the company's financial flexibility. Their main focus is on meeting upcoming regulatory and clinical goals, such as submitting the LOTIS-5 sBLA and releasing full LOTIS-7 data by the end of the specified time frame."
datetime: "2026-06-24T11:32:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290690105.md)
  - [en](https://longbridge.com/en/news/290690105.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290690105.md)
---

# ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

The company is anticipating a planned reduction of around 17% in its workforce, with estimated annual savings of about $10 million. This move is aimed at increasing the company's financial flexibility. Their main focus is on meeting upcoming regulatory and clinical goals, such as submitting the LOTIS-5 sBLA and releasing full LOTIS-7 data by the end of the specified time frame.

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)

## Related News & Research

- [ADC Therapeutics completes LOTIS-7 Phase 1b enrollment for Zynlonta-glofitamab combo in r/r DLBCL](https://longbridge.com/en/news/291272696.md)
- [ADC Therapeutics reports positive LOTIS-5 PFS results; plans pre-sBLA meeting and Q4 2026 sBLA](https://longbridge.com/en/news/288624565.md)
- [Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway](https://longbridge.com/en/news/293951548.md)
- [Chemed Q2 revenue beats estimates, helped by VITAS segment growth](https://longbridge.com/en/news/294109919.md)
- [Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestone](https://longbridge.com/en/news/293970382.md)